Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Trial Details

NCT ID
NCT06890598
Phase
PHASE3
Sponsor
Eli Lilly and Company
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Olomorasib
  • Pembrolizumab
  • Durvalumab
  • Placebo
Locations (sample)
  • Huntsville, Alabama, United States|34.7304,-86.58594
  • Mobile, Alabama, United States|30.69436,-88.04305
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Springdale, Arkansas, United States|36.18674,-94.12881

Key Eligibility Criteria

  • Histological or cytological confirmation of NSCLC.
  • Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic…
  • Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection.
  • Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →